The India anti-fungal drugs market size reached USD 509.90 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 671.14 Million by 2033, exhibiting a growth rate (CAGR) of 3.10% during 2025-2033. The India anti-fungal drugs market share is expanding, driven by the rising incidence of diabetes that creates an ideal environment for fungal growth, along with the increasing access to reliable treatment for fungal infections in hospitals, clinics, and diagnostic centers.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 509.90 Million |
Market Forecast in 2033 | USD 671.14 Million |
Market Growth Rate 2025-2033 | 3.10% |
Rising incidence of diabetes
The high prevalence of diabetes is fueling the India anti-fungal drugs market growth. As per the information published on the official website of the National Library of Medicine, the incidence of type 2 diabetes mellitus (T2DM) is increasing in India, with estimates reaching 134 million cases by 2045. Diabetic patients are more prone to fungal infections due to weakened immune systems and elevated blood sugar levels, which foster a suitable setting for fungal proliferation. Conditions like oral thrush, fungal nail infections, vaginal candidiasis, and mucormycosis (black fungus) are commonly seen in people with diabetes, driving the demand for effective anti-fungal medications. Poorly managed diabetes further raises the risk of severe and recurring fungal infections, making antifungal treatment a necessity for many patients. Additionally, the widespread use of broad-spectrum antibiotics and steroids in diabetes treatment can disrupt the body's natural microbial balance, leading to secondary fungal infections that require immediate care. The increasing awareness among diabetic patients about infection risks is encouraging the usage of both prescription and over the counter (OTC) antifungal treatments. Healthcare providers are emphasizing regular screenings for fungal infections in diabetic patients, further contributing to the market growth. As diabetes cases continue to rise, the requirement for reliable and effective antifungal drugs is rising, making it a key segment in India's pharmaceutical market.
Expanding healthcare infrastructure
The expansion of healthcare infrastructure is offering a favorable India anti-fungal drugs market outlook. Under the Indian Union Budget 2025-26, the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM), designed to enhance healthcare facilities, experienced a 31.3% increase in funding, from INR 3,200 crore in FY2024-25 to INR 4,200 Crore. This rise is anticipated to aid in the creation of new primary and secondary healthcare facilities, especially in neglected areas. With better medical facilities in both urban and rural areas, more people are getting diagnosed and treated for fungal infections that might have previously gone unnoticed. The rise of specialized dermatology and infectious disease clinics is also driving the demand for antifungal medications, as doctors can identify and treat conditions like ringworm, candidiasis, and mucormycosis more efficiently. Government initiatives to strengthen healthcare services, including the construction of new hospitals and the broadening of primary healthcare centers, are ensuring that antifungal treatments reach a larger population. The increasing investments in medical research and development (R&D) activities is also leading to the availability of newer and more effective antifungal drugs.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the regional level for 2025-2033. Our report has categorized the market based on drug class, indication, infection type, route of administration, distribution channel, and end user.
Drug Class Insights:
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes azoles, echinocandins, polyenes, allylamines, and others.
Indication Insights:
A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes candidiasis, aspergillosis, dermatophytosis, mucormycosis, and others.
Infection Type Insights:
The report has provided a detailed breakup and analysis of the market based on the infection type. This includes superficial fungal infection and systemic fungal infection.
Route of Administration Insights:
A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes parenteral, topical, oral, and others.
Distribution Channel Insights:
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacy, hospital pharmacy, and online pharmacy.
End User Insights:
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes homecare, hospitals and clinics, and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North India, South India, East India, and West India.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Drug Classes Covered | Azoles, Echinocandins, Polyenes, Allylamines, Others |
Indications Covered | Candidiasis, Aspergillosis, Dermatophytosis, Mucormycosis, Others |
Infection Types Covered | Superficial Fungal Infection, Systemic Fungal Infection |
Route of Administrations Covered | Parenteral, Topical, Oral, Others |
Distribution Channels Covered | Retail Pharmacy, Hospital Pharmacy, Online Pharmacy |
End Users Covered | Homecare, Hospitals and Clinics, Others |
Regions Covered | North India, South India, East India, West India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |